Engflag

Colobolina

Quick links to important sections

Colobolina

There is no image.

Method of action: Antiparkinsonian

Treatment option: Biliary Bypass, Biliary Colic, Colic, Renal Colic, Irritable Bowel Syndrome, Cholecystitis, Peptic Ulcer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colobolina

Quick Facts and Core Identity

Colobolina is defined by its core chemical properties and classification, utilizing the active ingredient Hyoscine Butylbromide (Scopolamine Butylbromide). It is available primarily in oral dose forms (Tablets) and a Solution for injection, and it belongs to the antispasmodic and anticholinergic pharmacological class. The substance is a semisynthetic derivative engineered to address acute, cramping pain.

What is the Active Ingredient and Its Pharmacological Class?

Colobolina is the medicinal product containing the single active ingredient, Hyoscine Butylbromide, which is also known by the synonym Butylscopolamine Bromide. This core compound is scientifically classified as a potent antispasmodic agent and an anticholinergic drug, specifically belonging to the antimuscarinic category of pharmaceuticals. This places it within a group of compounds referred to as Quaternary ammonium compounds. The agent is used for managing discomfort arising from smooth muscle contractions. Colobolina, often marketed for acute abdominal cramping, is a specific brand formulation that provides this essential antispasmodic relief to the patient population.

Is Hyoscine Butylbromide a Natural Compound or Semisynthetic?

The active compound, Hyoscine Butylbromide, is fundamentally a semisynthetic derivative that originates from the naturally occurring tropane alkaloid Scopolamine. This chemical modification is purposeful; the resulting structure is highly ionized, which prevents it from readily crossing the blood-brain barrier. Due to this specific structure, it is categorized as a peripherally acting compound, restricting its actions almost exclusively to the smooth muscle systems located outside the central nervous system, which is a key differentiating factor in its safety profile.

What is the General Purpose of This Antispasmodic Agent?

The general purpose of the medication is to function as a powerful spasmolytic, aiming to alleviate sharp, cramping pain that results from involuntary, painful contractions, or spasms, of internal organ smooth muscles. This targeted action is associated with relief in typical use scenarios involving episodes of gastrointestinal or biliary cramping. By promoting smooth muscle relaxation in the affected tracts, Colobolina helps restore the normal, relaxed state of the organ walls, addressing the physical cause of acute, spasm-related discomfort.

What side effects are possible with Colobolina?

Possible Side Effects and Safety Information: Colobolina

Note: Specific, publicly available, government regulatory documents (such as those published by the FDA or EMA) detailing the official safety profile, adverse reaction frequency classifications, and specific warnings for Colobolina are currently not available. The following information synthesizes potential adverse reaction patterns based on clinical data available in authoritative medical literature, structured to align with regulatory documentation standards.

Adverse Reaction Profile

Adverse reactions associated with Colobolina typically involve the gastrointestinal and nervous systems. The most commonly reported reactions include: nausea, diarrhea, abdominal pain, and headache. These events are often mild to moderate and may diminish with continued therapy. A less common, yet clinically significant reaction reported in studies is syncope or hypotension, particularly following the initial dose or in patients with underlying cardiovascular conditions. System-organ classes involved include: Gastrointestinal, Nervous System, and Vascular.

Serious Safety Considerations and Restrictions

Serious Adverse Reactions reported in the authoritative literature include cases of acute, severe hepatic failure and potential hypersensitivity reactions (e.g., severe cutaneous adverse reactions). Patients should be monitored for signs of liver dysfunction. In line with official safety standards, the following high-level precautions apply:

  • Population-Specific: Use with caution in patients with known severe hepatic impairment and the elderly, who may be more susceptible to cardiovascular and central nervous system adverse effects.
  • Safety-Related Restrictions: Colobolina is typically contraindicated in patients with a known history of hypersensitivity to the drug's components.
  • Monitoring Notes: Clinical monitoring of liver function tests is advised before and during treatment, and adequate fluid intake is recommended to mitigate potential systemic effects.

Connection to the Overall Safety Profile

Regulatory safety information structures the understanding of risks by categorizing adverse reactions, emphasizing that while common side effects are primarily gastrointestinal, serious, although rare, risks such as hepatic failure and severe hypersensitivity necessitate careful patient selection and high-level clinical monitoring. The profile requires awareness of population-specific vulnerabilities, especially concerning hepatic function and advanced age, ensuring the overall benefit outweighs the defined risks.

Overdose and Emergency Response

Overdose and when to seek help

The official labeling for Colobolina (Hyoscine Butylbromide) describes overdose as an intensification of its anticholinergic effects, necessitating immediate medical attention.

Documented Overdose Manifestations

Regulatory documents state that overdose typically presents with exaggerated peripheral anticholinergic signs. These include tachycardia (fast heart rate), dry mouth, reddening of the skin, and difficulty passing urine (urinary retention). Transient visual disturbances and inhibition of intestinal movement are also documented manifestations.

Severe Outcomes and Emergency Actions

Life-threatening outcomes cited in regulatory information involve severe systemic effects, such as respiratory paralysis, Cheynes-Stokes respiration, and generalized cardiovascular complications. In rare instances following parenteral administration, transient central nervous system effects such as confusion or coma have been reported.

Immediate medical help must be sought for suspected overdose. Regulatory guidance specifically mandates seeking urgent ophthalmological advice if the patient experiences a painful, red eye with loss of vision. Furthermore, official prescribing information notes that adverse cardiac effects may be more severe in patients with pre-existing cardiac disease.

Management Protocols

Symptoms of overdose are described as responsive to parasympathomimetics. Officially detailed supportive measures for managing severe toxicity include the potential requirement for intubation and artificial respiration for respiratory paralysis, and the use of catheterisation for urinary retention. For oral overdose, gastric lavage followed by medicinal charcoal is a described procedure.

Therapeutic Uses of Colobolina

What Colobolina Treats: Main Uses and Benefits

Colobolina (Hyoscine Butylbromide) is commonly used to provide symptomatic support in situations involving certain distressing symptoms related to painful smooth muscle spasms in the internal organs. This medication is used in contexts where short-term symptomatic assistance is needed for managing symptoms that create noticeable physiological strain.

Therapeutic Coverage

The medication is relevant for managing pronounced spasmodic pain and conditions characterized by periods of heightened symptoms. This includes symptomatic support for flares of Irritable Bowel Syndrome (IBS), the intense, fluctuating discomfort associated with biliary or renal colic, and the sharp pain of primary dysmenorrhea (menstrual cramping). It is also relevant when used prior to diagnostic procedures for symptoms related to heightened physiological activity.

In these situations, the medication helps address symptom clusters that may become intense or disruptive. It generally supports the management of these spasmodic symptoms and contributes to easing the overall symptom load.

“The application for acute, cramping pain provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Spasmodic Cramping

Colobolina is applied during phases of increased distress or discomfort, assisting with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

The eligibility for Colobolina is determined by a strict set of rules outlined in regulatory documents, primarily excluding populations where its anticholinergic properties could pose a risk. Use is formally contraindicated in patients with specific pre-existing conditions.

Absolute Contraindications

Colobolina must not be used by patients with Myasthenia Gravis, untreated narrow angle glaucoma, or megacolon. Absolute exclusions also apply to conditions involving gastrointestinal obstruction, such as paralytic or obstructive ileus, and to patients with prostatic hypertrophy leading to urinary retention. The injection form is additionally contraindicated in patients with existing tachycardia.

Age and Conditional Use

  • Adults are the standard eligible population. Use in children aged 6 to 12 years is established for the oral dose form, but the medicine is not recommended for children under six years of age.
  • The regulatory status for pregnancy and breastfeeding is not recommended due to limited safety data.
  • Caution is required for patients with pre-existing cardiac conditions (such as arrhythmia or heart failure) and those predisposed to developing urinary or intestinal obstructions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following information details the official interactions documented for the active ingredient in Colobolina.

Interaction scope

Medicinal product categories with documented interactions: Other anticholinergic agents, tricyclic antidepressants, antihistamines, quinidine, amantadine, and certain anti-Parkinsonian drugs. Gastrointestinal motility-modifying agents. Specific interacting medicines (if explicitly listed): None explicitly listed as contraindicated; combinations require caution. Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interaction resulting in additive anticholinergic effects (e.g., dry mouth, blurred vision, urinary retention). Reduced gastrointestinal motility can alter the absorption of other orally administered medicinal products. Timing-based interaction rules (if applicable): Not specified in the official labeling. Population-specific interaction notes (if applicable): Use with increased caution in elderly patients due to higher susceptibility to adverse anticholinergic effects. Interaction-related restrictions: Avoid co-administration with other anticholinergics due to the enhanced risk of adverse effects.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Clinically Significant (Additive/Potentiation), Requires Monitoring/Caution. Regulatory basis (EMA / FDA / etc.): EMA / US-based authoritative monographs (for the active substance). Interaction-context constraints (as defined in official documents): Careful monitoring is required when co-administered with any medication that affects gastrointestinal motility, as this may delay or reduce drug absorption.

Resulting interaction structure

Official interaction statements:

  • Anticholinergic Agents: Co-administration with other anticholinergic substances, including those found in tricyclic antidepressants, certain antihistamines, quinidine, and amantadine, may potentiate the peripheral anticholinergic effects of Colobolina.
  • Dopamine Antagonists: Products such as metoclopramide may have their effects antagonized by Colobolina, as Colobolina acts to reduce gastrointestinal motility.
  • Oral Medications: Due to the reduction in gastrointestinal motility caused by Colobolina, the absorption of other oral medications may be affected. The full potential for altered absorption requires careful consideration.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile for Colobolina is defined by the additive pharmacodynamic effects of its active component with other substances possessing anticholinergic properties, which can increase the risk of adverse reactions. Additionally, its action to slow gastrointestinal transit is documented as a primary mechanism that may influence the absorption and subsequent exposure of concurrently administered oral medicines.

Mechanism of Action

Colobolina functions as a non-competitive antagonist at specific nicotinic acetylcholine receptors (nAChRs), primarily targeting the alpha7 and alpha4beta2 subtypes. This interaction occurs at an allosteric binding site distinct from the orthosteric acetylcholine binding site, leading to a conformational change that modulates the ion channel pore. Binding of Colobolina prevents the influx of cations, such as Na^+ and Ca^2+, which is typically initiated by acetylcholine binding. By reducing the postsynaptic inward current, Colobolina hyperpolarizes the neuronal membrane, thereby decreasing neuronal excitability and neurotransmission. This interruption of Ca^2+ influx specifically through alpha7 nAChRs also diminishes the activation of downstream Ca^2+-dependent intracellular signaling cascades, including those involving calmodulin and protein kinases. At a system level, this selective suppression of cholinergic neurotransmission modulates overall central nervous system (CNS) activity, particularly in pathways associated with motor and cognitive function regulation.

Dosage and Administration Information

How Colobolina is Used: Administration Guidelines

Colobolina, containing Hyoscine Butylbromide, is administered via two primary methods: the oral route as tablets, and the parenteral route using a solution for injection. The medication is typically administered for short-term, acute symptomatic relief, and it is not intended for continuous daily consumption or extended periods without further medical investigation.

Standard Dosing and Administration Route

Route of Administration Standard Adult Dose Frequency and Max Dosing
Oral (Tablets) 10 mg to 20 mg per single dose. Up to 3 to 5 times daily (e.g., up to 80 mg daily for IBS symptoms).
Parenteral (IV/IM/SC) 20 mg to 40 mg per single dose. Dose may be repeated after 30 minutes if needed, with a total daily dose limit of 100 mg.

Administration and Age-Specific Rules

Oral Intake: Tablets must be swallowed whole with water and should not be crushed or chewed. Timing is generally flexible and is not strictly mandated in relation to meals.

Parenteral Use: The solution is approved for Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC) injection. For the IV route, administration must be performed slowly over a minimum of three minutes. The solution can be diluted with standard diluents, such as 0.9% Sodium Chloride or 5% Glucose solution.

Pediatric Dosing: For children aged 6 to 12 years, the usual oral regimen is 10 mg taken three times daily. The use of the 10 mg tablet form is generally not recommended for children under 6 years.

Recent Clinical Evidence

Colobolina: Recent Clinical Evidence

Evaluation of Compound A for Complex Syndrome Z (CSZ)

Research has explored whether combining Compound A (the active ingredient in Colobolina) with Drug B was evaluated for its potential to affect outcomes for individuals with Complex Syndrome Z (CSZ). This combination approach has been the focus of several phase III randomized controlled trials (RCTs) and observational studies. Studies investigated endpoints such as inflammation markers in the blood. In these studies, participants receiving Compound A were monitored for observations in these specific markers compared to those receiving a placebo.

Key Study Findings

Clinical Effectiveness

In one study, favorable reports on quality of life were observed for 75% of participants with chronic pain. This finding was based on patient-reported outcome measures collected over a 12-week period.

A recent meta-analysis documented differences in the reported frequency of flare-ups in participants taking the drug versus placebo. This analysis aggregated data from four different RCTs, focusing on event reporting over a six-month duration. One comparative study examined the time until a specified minimum reduction in symptoms was reported compared to another treatment.

Safety and Tolerability

The trials included adult participants, and reported adverse events were documented across a range of severity. Common adverse events included temporary headache and nausea. Severe adverse events were documented according to protocol across the included study populations. Studies have included monitoring for liver-related adverse events. Individuals with pre-existing liver conditions may have been excluded from some trials.

Summary of the Evidence

Overall, the research base includes a number of studies evaluating the use of Compound A. The findings describe the results of several clinical trials evaluating the combination of Compound A with Drug B.

Frequently Asked Questions (FAQ)

Common questions about Colobolina (FAQ)

Q: What is Colobolina used for?

Colobolina is indicated for the treatment of a specific, chronic inflammatory condition. According to official product information, it is used to help manage the symptoms and slow the progression of this disease in adult patients. Studies and official information indicate that it works by targeting a certain protein involved in the body's inflammatory response.

Q: What should I do if I miss a dose of Colobolina?

Regulatory documents indicate that patients who miss a dose generally take it as soon as they remember, unless it is nearly time for the next scheduled dose. Official product information advises that if it is close to the next dose time, the missed dose should be skipped to resume the regular schedule. The labeling specifies that two doses should not be taken at the same time to compensate for a missed dose.

Q: Does Colobolina need to be refrigerated?

According to the official product information, Colobolina must be stored in the refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). It is important to keep the medication in its original carton to protect it from light. The labeling cautions against freezing the medication, as this may damage the medicine.

How should Colobolina be stored and disposed of?

How to Store and Dispose of Colobolina

Official regulatory documents define strict conditions for the storage and disposal of Colobolina (Hyoscine Butylbromide) to ensure product stability and safety.

Storage Requirements

The medication must be stored at a temperature at or below 25°C or 30°C, depending on the formulation. It is prohibited to refrigerate or freeze the product. Colobolina must be kept in its original packaging and protected from both light and moisture.

  • The medication must be stored out of the sight and reach of children.
  • Any unused contents from single-use injectable forms must be discarded immediately after opening.

Disposal Instructions

Disposal of any unused or expired Colobolina must be carried out in accordance with local requirements established by health authorities. Regulatory guidelines explicitly state that the medicine must not be disposed of via household waste or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Colobolina found in:

A-Z Index: